QS Investors LLC lessened its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 3.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 220,818 shares of the biopharmaceutical company’s stock after selling 8,520 shares during the period. QS Investors LLC owned about 0.53% of PTC Therapeutics worth $3,683,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Parametric Portfolio Associates LLC lifted its position in PTC Therapeutics by 31.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 52,779 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 12,563 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in PTC Therapeutics by 1.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 528,586 shares of the biopharmaceutical company’s stock worth $9,689,000 after buying an additional 5,960 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in PTC Therapeutics during the 2nd quarter worth about $142,000. American Century Companies Inc. acquired a new position in PTC Therapeutics during the 3rd quarter worth about $3,936,000. Finally, Prudential Financial Inc. lifted its position in PTC Therapeutics by 365.1% during the 3rd quarter. Prudential Financial Inc. now owns 51,227 shares of the biopharmaceutical company’s stock worth $1,025,000 after buying an additional 40,212 shares in the last quarter. Institutional investors own 91.87% of the company’s stock.
Shares of PTC Therapeutics, Inc. (NASDAQ PTCT) opened at $30.20 on Friday. PTC Therapeutics, Inc. has a twelve month low of $8.12 and a twelve month high of $31.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.04 and a quick ratio of 2.90.
PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.17. The firm had revenue of $78.00 million during the quarter, compared to analysts’ expectations of $78.59 million. PTC Therapeutics had a negative return on equity of 50.75% and a negative net margin of 40.64%. The company’s quarterly revenue was up 209.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.78) EPS. research analysts anticipate that PTC Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.
Several brokerages recently issued reports on PTCT. Barclays reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. boosted their price objective on PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a report on Friday, November 24th. Credit Suisse Group reissued a “buy” rating and set a $28.00 price objective on shares of PTC Therapeutics in a report on Tuesday, January 30th. Zacks Investment Research cut PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, January 13th. Finally, ValuEngine raised PTC Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $23.57.
In other news, CEO Stuart Walter Peltz sold 2,230 shares of the company’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total value of $40,206.90. Following the completion of the sale, the chief executive officer now directly owns 26,646 shares of the company’s stock, valued at approximately $480,427.38. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 2,719 shares of company stock valued at $48,848 over the last three months. Company insiders own 8.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/03/17/ptc-therapeutics-inc-ptct-stake-lowered-by-qs-investors-llc.html.
PTC Therapeutics Profile
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.